recombinant human tissue-type plasminogen activator derivative (rPA)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for recombinant human tissue-type plasminogen activator derivative (rPA), covering 2019-10-11 to 2019-10-11. Get the full timeline:
Most recent: Clinical Trial Update: Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) [Phase 2]